Catalyst Pharmaceuticals Inc(CN2)

Description: Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

---

Keywords: Biopharmaceutical Autoimmune Disease Neurological Diseases Myasthenia Gravis Spinal Muscular Atrophy Sabril Biomarin Pharmaceutical Gravis Lambert Eaton Myasthenic Syndrome Amifampridine Lambert–Eaton Myasthenic Syndrome Neuromuscular Junction

---

Home Page: www.catalystpharma.com

355 Alhambra Circle
Coral Gables, FL 33134
United States
Phone: 305 420 3200

---

Officers

Exchange: F

Country: DE : Germany

Currency: Euro (€)